C. Brooke Adams, PharmD, BCOP

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, challenges the assumption that oral agents (belumosudil) are inherently more convenient than intravenous therapy (axatilimab) by highlighting that the intravenous schedule creates structured monitoring touchpoints and that mechanism differences—not route alone—should drive sequencing decisions in heavily pretreated populations.

Brooke Adams, PharmD, BCOP, walks through the operational mechanics of transitioning cGVHD patients to community settings: coordination touchpoints, common failure points, and 90-day post-transition checkpoints that confirm a successful handoff.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, addresses the tension between objective NIH scoring and subjective patient experience, and how pharmacists can document patient-reported outcomes to support clinical recommendations, particularly when partial responses demonstrate meaningful functional improvement.

Brooke Adams, PharmD, BCOP, explores how patient narratives on axatilimab inform treatment decisions, moving beyond National Institutes of Health response criteria to functional outcomes—return to work or family activities, reduction in pain or skin discomfort, improved sleep—and how these improvements may exceed what clinical response rates alone predict.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, describes the pharmacist-to-pharmacist handoff workflow when patients with cGVHD transition from the transplant center to outpatient or home infusion settings, including essential documentation elements, baseline assessments, and red-flag symptoms that require immediate clinical contact.

Brooke Adams, PharmD, BCOP, identifies the clinically meaningful adverse effects every pharmacist must monitor—periorbital edema, hepatic enzyme elevations, fatigue—and specifies intervention thresholds (grading, dose modifications, hold criteria) that should trigger escalation conversations with prescribers.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, discusses how axatilimab performs in actual practice versus what AGAVE-201 predicted, including responses in organ manifestations not well-represented in the trial and how real-world monitoring protocols have evolved based on accumulated clinical experience.

Brooke Adams, PharmD, BCOP, walks through the axatilimab trial data (AGAVE-201) and belumosudil trial populations, highlighting how differences in study design, patient characteristics, and end points affect pharmacist interpretation and comparability, and what gaps exist in the evidence base for specific organ manifestations.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, translates the CSF1R-targeted mechanism into practical pharmacist workflows: distinct toxicity profiles (periorbital edema, hepatic enzyme elevations), drug interaction review for polypharmacy, and how to communicate the mechanistic rationale to patients and community pharmacy teams.

Brook Adams, PharmD, BCOP, explains axatilimab's distinct mechanism targeting the CSF1R pathway on macrophages and monocytes—as opposed to T-cell pathways (ibrutinib) or JAK/STAT signaling (ruxolitinib)—and why this mechanistic differentiation is clinically meaningful when patients have already progressed on other agents.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, discusses how axatilimab fits into formulary placement and treatment sequencing decisions at her institution, including how the multidisciplinary transplant team aligns on when to initiate therapy and whether clinical scenarios exist in which the conversation might occur earlier than strictly in the third line.

Brooke Adams, PharmD, BCOP, describes the clinical reality of third-line cGVHD: patients with relapsed or refractory disease after steroids, calcineurin inhibitors, and at least 1 approved second-line agent.

Bispecific antibodies are reshaping multiple myeloma care through improved safety and expanded outpatient use.

Pharmacists and clinicians share strategies to streamline training, collaboration, and patient care with BTCEs.

Experts detail the workflows and decisions behind launching complex bispecific therapies.

Linvoseltamab joins 3 other bispecific T-cell–engaging antibodies in multiple myeloma, offering deep and durable responses in heavily pretreated patients.

Explore the latest advancements in myelofibrosis therapies, including innovative treatments and the evolving role of pharmacists in patient care.

New findings on myelofibrosis treatments reveal the impact of anemia on survival and the benefits of momelotinib for transfusion independence.

Pharmacists play a crucial role in managing myelofibrosis treatment, ensuring patient education, medication access, and monitoring for adverse effects.

Experts discuss the need for improved clinical trials in myelofibrosis, focusing on disease modification, patient outcomes, and potential new therapies.

Explore how real-world evidence shapes myelofibrosis treatment, focusing on biomarker utilization and safety profiles of JAK inhibitors.

Explore the latest advancements in myelofibrosis treatments, including Fedratinib, Pacritinib, and Momelotinib, and their clinical impacts.

Explore the latest advancements in JAK inhibitors for myelofibrosis, highlighting their unique mechanisms and clinical implications for patient care.

Explore the evolution of myelofibrosis treatments, from traditional therapies to groundbreaking JAK inhibitors, and the ongoing need for innovative solutions.

Explore the long-term effects of myelofibrosis and the importance of early diagnosis and treatment for better patient outcomes.

Explore the critical role of patient characteristics and biomarker testing in managing myelofibrosis, enhancing prognosis and treatment strategies.

Oncology pharmacists discuss myelofibrosis management, focusing on anemia, JAK inhibitors, and improving patient outcomes through tailored care.

Explore expert insights on managing myelofibrosis, focusing on anemia, JAK inhibitors, and enhancing patient care for better outcomes.

Second-line and later treatment options for synovial sarcoma are limited. Afamitresgene autoleucel is the first FDA-approved T-cell receptor therapy, demonstrating long-lasting responses and tolerable adverse effects in pretreated patients.

Chronic graft-vs-host disease (cGVHD) is the leading cause of late, non-relapse mortality for patients who have undergone an allogeneic hematopoietic stem cell transplant. Axatilimab, which has durable responses and an attractive safety profile, offers a novel mechanism of action for the treatment for patients who have not succeeded with at least 2 prior lines of systemic therapy.